Medtronic (MDT) closed the most recent trading day at $92.2, moving +2.38% from the previous trading session.
Medtronic's shares have sharply rallied over the last six months. The medtech giant's growth catalysts include a best-in-class product (Affera) in a fast-growing $11 billion space and a massive opportunity in the underpenetrated urge urinary incontinence market. Medtronic possesses an A S&P credit rating with a stable outlook.
In the closing of the recent trading day, Medtronic (MDT) stood at $94.21, denoting a -1.76% move from the preceding trading day.
The latest trading day saw Medtronic (MDT) settling at $95.34, representing a -1.24% change from its previous close.
In the last decade, Medtronic (MDT) stock has returned a notable $52 Bil back to its shareholders through cold, hard cash via dividends and buybacks. Let's look at some numbers and compare how this payout power stacks up against the market's biggest capital-return machines.
Medtronic (MDT) concluded the recent trading session at $96.5, signifying a -1.4% move from its prior day's close.
Medtronic plc - Special Call Company Participants Ryan Weispfenning - VP & Head of Investor Relations Emily Elswick Conference Call Participants Ryan Zimmerman - BTIG, LLC, Research Division Nathan Treybeck - Wells Fargo Securities, LLC, Research Division Christopher Pasquale - Nephron Research LLC Shagun Singh Chadha - RBC Capital Markets, Research Division Michael Polark - Wolfe Research, LLC Danielle Antalffy Presentation Ryan Weispfenning VP & Head of Investor Relations Okay. Hello, everyone.
An “October Surprise” is usually a significant, late-breaking news event that generally occurs just before a November election and has the potential to influence its outcome.
Medtronic (MDT) closed the most recent trading day at $97.7, moving +2.33% from the previous trading session.
Medtronic plc (NYSE:MDT ) Bank of America Global Healthcare Conference 2025 September 24, 2025 9:10 AM EDT Company Participants Thierry Pieton - Executive VP & CFO Presentation Unknown Analyst We're glad to have the Medtronic CFO, Thierry Pieton, here with us. So welcome.
Medtronic remains a Buy for long-term investors, offering steady growth, durable income, and an attractive valuation below historical averages. MDT delivered solid fiscal Q1 2026 results, with 8.4% revenue growth and standout performance in Cardiac Ablation and Diabetes segments. The upcoming diabetes segment spinoff is expected to improve operating margins and reinforce MDT's growth trajectory.
Medtronic plc (NYSE:MDT ) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 4:50 PM EDT Company Participants Thierry Pieton - Executive VP & CFO Conference Call Participants Patrick Wood - Morgan Stanley, Research Division Presentation Patrick Wood MD of Equity Research I think we'll kick things off. Thanks so much, everybody.